List View

By /

Clear

Displaying 2,251 - 2,275 of 2,995

CAR-T Cell in NSCLC: Is it Feasible?

CAR-T Cell in NSCLC: Is it Feasible?

Developing New Anti-CTL4s for NSCLC: Is There Any Role?

Developing New Anti-CTL4s for NSCLC: Is There Any Role?

Exon 20 and Uncommon EGFR Sensitive Mutations

Exon 20 and Uncommon EGFR Sensitive Mutations

Frontline: What are We Adding to Checkpoint Inhibitors and Chemotherapy?

Frontline: What are We Adding to Checkpoint Inhibitors and Chemotherapy?

Future Challenges for Immunotherapy in the Fight Against NSCLC

Future Challenges for Immunotherapy in the Fight Against NSCLC

Health Care Disparities in Lung Cancer Genomic Profiling

Health Care Disparities in Lung Cancer Genomic Profiling

HER-3 as a New Target in NSCLC

HER-3 as a New Target in NSCLC

How to Improve Targeted Therapy in NSCLC? Where are the Major Gaps?

How to Improve Targeted Therapy in NSCLC? Where are the Major Gaps?

How to Rescue Patients from Osimertinib Resistance

How to Rescue Patients from Osimertinib Resistance

How to Start a Lung Cancer Screening Program

How to Start a Lung Cancer Screening Program

KRAS mutant NSCLC: What is the Standard of Care Now?

KRAS mutant NSCLC: What is the Standard of Care Now?

KRAS: Deciphering the Mechanism of Resistance To First Generation KRAS Inhibitors

KRAS: Deciphering the Mechanism of Resistance To First Generation KRAS Inhibitors

Lack of Equity in Clinical Outcomes in African American and Hispanics with NSCLC

Lack of Equity in Clinical Outcomes in African American and Hispanics with NSCLC

Mechanisms of Resistance to ALK Inhibitors

Mechanisms of Resistance to ALK Inhibitors

Methylation, Proteomics and Other Efforts for Early Lung Cancer Detection

Methylation, Proteomics and Other Efforts for Early Lung Cancer Detection

Minimal Residual Disease (MRD) as Detected by Liquid Biopsy: Where are We Going?

Minimal Residual Disease (MRD) as Detected by Liquid Biopsy: Where are We Going?

MRD to Decide Perioperative Management in the Era of Immuno-Oncology

MRD to Decide Perioperative Management in the Era of Immuno-Oncology

Neoadjuvant Immunotherapy Position

Neoadjuvant Immunotherapy Position

Novel Therapies for Thymic Malignancies

Novel Therapies for Thymic Malignancies

NRG1 as Target in NSCLC?

NRG1 as Target in NSCLC?

Optimal Management of Extensive SCLC (1st and 2nd Line)

Optimal Management of Extensive SCLC (1st and 2nd Line)

Optimal Management of Limited Stage SCLC

Optimal Management of Limited Stage SCLC

Optimal Surgical Approach for Mesothelioma

Optimal Surgical Approach for Mesothelioma

Overcoming T-Cell Exhaustion

Overcoming T-Cell Exhaustion

Pan-KRAS Inhibitors: Where are We Going?

Pan-KRAS Inhibitors: Where are We Going?